Affordable Access

Publisher Website

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

Authors
Publication Date
Volume
333
Issue
7579
Identifiers
DOI: 10.1136/bmj.38993.731725.be
Keywords
  • Adult
  • Aged
  • Aged
  • 80 And Over
  • Arterial Occlusive Diseases
  • Coronary Disease
  • Cost-Benefit Analysis
  • Diabetic Angiopathies
  • Female
  • Humans
  • Hydroxymethylglutaryl-Coa Reductase Inhibitors
  • Life Expectancy
  • Male
  • Middle Aged
  • Quality-Adjusted Life Years
  • Risk Factors
  • Simvastatin
Disciplines
  • Medicine

Abstract

To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages with differing risks of vascular disease.

There are no comments yet on this publication. Be the first to share your thoughts.